NICE Single Technology Appraisal Guidance No194 – Denosumab for
the treatment of therapy-induced bone loss in non-metastatic
prostate cancer
This NICE Guidance was
published 28 July 2010. The web reference for the appraisal and
other related documents is: http://guidance.nice.org.uk/TA194
The guidance states that NICE is unable to
recommend the use in the NHS of denosumab for the treatment of
therapy-induced bone loss in non-metastatic prostate cancer because
no evidence submission was received from the manufacturer or
sponsor of the technology.
NHSScotland should note that:
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHS Scotland.
2. The Scottish Medicines Consortium (SMC) is
awaiting notification from the manufacturer of Denosumab on their
submission plans.
If you need further assistance, please contact
Eleanor Brownlee in the first instance (tel 0141 225 6873 or email
eleanor.brownlee@nhs.net).
Published Date: 28 July 2010
